Aprea Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aprea Therapeutics, Inc. on June 17, 2024. The Company is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. The report primarily addresses a significant clinical milestone achieved on the filing date.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. As a clinical-stage company reporting a specific event, no financial metrics are disclosed in this document.
Material Changes
The primary material event reported is the dosing of the first patient in the ACESOT-1051 Phase 1 clinical trial. This trial evaluates the Company's oral WEE1 inhibitor, APR-1051. Additionally, the Company updated its corporate presentation slide deck on the same date.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical milestone. The filing incorporates a press release and an updated corporate presentation by reference but does not provide specific forward-looking guidance, risk factors, or contingencies within the text of this 8-K. Investors should refer to the incorporated exhibits for detailed outlooks.
Key Facts for Investor Verification
- First patient dosed in the ACESOT-1051 Phase 1 trial for APR-1051 on June 17, 2024.
- APR-1051 is an oral WEE1 inhibitor.
- Review Exhibit 99.1 for the full press release details.
- Review Exhibit 99.2 for the updated corporate presentation.
- No financial data is provided in this specific filing.